Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study Jun 17, 2019
Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update May 1, 2019
Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”) Apr 26, 2019
Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates Apr 8, 2019
